Skip to main content

Posts

Showing posts with the label macrolides

#Macrolide #Resistance and P1 Cytadhesin Genotyping of #Mycoplasma pneumoniae during #Outbreak, #Canada, 2024–2025

  Abstract We investigated macrolide resistance and P1 genotypes of Mycoplasma pneumoniae during the 2024–2025 outbreak in Hamilton, Ontario, Canada . Macrolide resistance remained stable at ≈10%–20%, but significant shifts in P1 genotype distribution and resistance rates in P1 types occurred, indicating notable changes in M. pneumoniae molecular epidemiology in Ontario since 2011–2012. Source:  Link:  https://wwwnc.cdc.gov/eid/article/31/12/25-0872_article ____

Post #COVID19 #resurgence of #Mycoplasma pneumoniae infections in French #children (ORIGAMI): a retrospective and prospective multicentre cohort study

  Summary Background Following a decline during the COVID-19 pandemic, Mycoplasma pneumoniae infections resurged in several countries . We aimed to characterise the clinical presentation of paediatric patients admitted to hospital for M pneumoniae during 2023 and 2024 in France. Methods We conducted a nationwide, multicentre, retrospective, and prospective observational study across 37 French paediatric hospitals (September, 2023–September, 2024). Children younger than 18 years who were hospitalised with laboratory-confirmed M pneumoniae infection (PCR or serology) were included. Demographics (excluding race), clinical features, laboratory and radiological findings, management, and outcomes data were described and analysed. Logistic regression was used to identify factors associated with paediatric intensive care unit (PICU) admission. The trial was registered at ClinicalTrials.gov (NCT06260371) and is complete. Findings We included 969 children and adolescents with M pneumoniae in...